Menu Search
Equities

Frontage Holdings Corp

1521:HKG.HS

Frontage Holdings Corp

Actions
  • Price (HKD)0.96
  • Today's Change-0.02 / -2.04%
  • Shares traded2.63m
  • 1 Year change-51.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 03:48 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Frontage Holdings Corporation is a holding company. The Company provides laboratory and related services to pharmaceutical and agrochemical companies as well as bioequivalence clinical and chemical services. The Company has two main divisions: Global Drug Discovery & Development Services and Global Laboratory Services. The Global Drug Discovery & Development Services division includes Drug Development Unit, Drug Discovery Unit and Pharmaceutical Product Development Unit. The Global Laboratory Services division offers laboratory testing support for clients involved in drug development. Its Global Laboratory Services encompass regulated and non-regulated bioanalysis (both small and large molecules), biomarkers, genomics, manufacturing and controls analytical testing, and central laboratory services. The Company's segments include North America and Europe, and PRC. The North America and Europe segment includes United States, Canada and Europe. The PRC segment includes China.

  • Revenue in HKD (TTM)2.02bn
  • Net income in HKD47.42m
  • Incorporated2018
  • Employees1.66k
  • Location
    Frontage Holdings Corp700 Pennsylvania DriveExton 19341-1129United StatesUSA
  • Phone+1 (610) 232-0100
  • Fax+1 (610) 232-0101
  • Websitehttps://www.frontagelab.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.